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Abstract
X-linked adrenoleukodystrophy (X-ALD) is the most common peroxisomal disorder. The disease is caused by
mutations in the ABCD1 gene that encodes the peroxisomal membrane protein ALDP which is involved in the
transmembrane transport of very long-chain fatty acids (VLCFA; ≥C22). A defect in ALDP results in elevated levels of
VLCFA in plasma and tissues. The clinical spectrum in males with X-ALD ranges from isolated adrenocortical
insufficiency and slowly progressive myelopathy to devastating cerebral demyelination. The majority of
heterozygous females will develop symptoms by the age of 60 years. In individual patients the disease course
remains unpredictable. This review focuses on the diagnosis and management of patients with X-ALD and provides
a guideline for clinicians that encounter patients with this highly complex disorder.
Keywords: X-linked adrenoleukodystrophy, X-ALD, Very long-chain fatty acids, VLCFA, ABCD1, Peroxisome, Myelin,
Leukodystrophy, Demyelinating disorder, Addison’s disease, Myelopathy
Disease names
X-linked adrenoleukodystrophy / adrenomyeloneuropa-
thy / Schilder’s disease / sudanophilic leukodystrophy
with melanoderma / encephalitis periaxialis diffusa /
Siemerling-Creutzfeld disease.
Definition
X-ALD is a metabolic disorder characterized by impaired
peroxisomal beta-oxidation of very long-chain fatty acids
(VLCFA; ≥ C22), which is reduced to about 30% of con-
trol levels [1,2]. Consequently, there is an accumulation
of VLCFA in plasma and all tissues, including the white
matter of the brain, the spinal cord and adrenal cortex.
[3]. It is caused by mutations in the ABCD1 gene located
on the X-chromosome [4]. Mutations in this gene cause
the absence or dysfunction of ALDP, a peroxisomal
transmembrane protein that transports VLCFacyl-CoA
esters from the cytosol into the peroxisome [5,6].
Epidemiology
With an estimated birth incidence of 1 in 17,000 new-
borns (male and female) [7], X-ALD is the most com-
mon peroxisomal disorder. It occurs in all regions of the
world [8]. Now that newborn screening has become
technically feasible and may be implemented in some
parts of the world [9], the true prevalence might be even
higher.
Clinical features of X-ALD
A short history
In retrospect, the first cases of X-ALD were probably
described in the late 19th century. In 1897 Heubner
described a young boy with rapidly progressive neurologic
deterioration consistent with X-ALD, classified as having
“diffuse sclerosis” on autopsy [10]. This designation was
used at the time for any disease of the white matter caus-
ing hardening of the tissue. Cases of “diffuse sclerosis”
that resemble X-ALD were also described in 1899 by Ceni
[11] and in 1910 by Haberfield and Spieler [12]. Shortly
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thereafter Schilder suggested that “diffuse sclerosis” was
too vague and proposed a more accurate pathological
classification of the leukodystrophies [13-15]. He
described several cases with lesions in the cerebral white
matter and perivascular inflammation that he named “en-
cephalitis periaxialis diffusa”. The syndrome of rapidly
progressive cerebral demyelination with inflammatory
changes in the white matter on autopsy became known as
“Schilder’s disease”. Many cases were described in the fol-
lowing fifty years [16]. Nevertheless, Siemerling and
Creutzfeldt are often credited for having described the
first case of X-ALD because they were the first to describe
the association of acute cerebral demyelination with clin-
ical and pathological signs of Addison’s disease [17].
X-ALD has remained an enigmatic disease for most of
the 20th century, although some suspected it might be a
metabolic disorder affecting both the central nervous
system and adrenal glands [18,19]. Based on the pres-
ence of lipid inclusions in adrenal glands, testis, brain
and Schwann cells, Schaumburg and Powers suggested
the term adrenoleukodystrophy for the disorder and
speculated it might be a lipid storage disorder [20]. This
hypothesis was confirmed when post-mortem biochem-
ical analysis of brain, adrenal glands and serum of seven
patients revealed the presence of cholesterol esters with
high amounts of fatty acids longer than C22. These fatty
acids were referred to as very long-chain fatty acids
(VLCFA) [21]. X-linked adrenoleukodystrophy now be-
came a distinct clinical entity with an associated bio-
chemical marker that could be used to confirm the
diagnosis in readily accessible materials like blood cells
and plasma [3].
Already in 1910 Addison’s disease associated with
spastic paraplegia was described [22]. Familial Addison
disease with or without spastic paraplegia was usually
considered to be a variant of hereditary spastic paraple-
gia [23,24]. In 1976, an X-linked adult onset progressive
myelopathy that was often associated with Addison’s dis-
ease was reported [25]. A year later, five more cases were
described and the term adrenomyeloneuropathy (AMN)
was proposed because of the involvement of the adrenal
cortex, spinal cord and peripheral nerves [26]. With
plasma VLCFA analysis as newly identified biomarker,
AMN was soon found to be a form of X-ALD thus
extending the phenotypic spectrum of X-ALD [3]. Now,
we classify the symptomatology of X-ALD in children
and adults in several phenotypes Table 1. They will be
discussed here in more detail.
Table 1 The X-ALD phenotypes
CCALD AdolCALD ACALD AMN Addison
only
Women with X-ALD
No cerebral disease Cerebral disease
Frequency (%) 31 - 35 4 - 7 2 - 5 40 - 46 20% of AMN patients
over a period of 10 years
Decreasing
with age
unknown how many
are symptomatic
Age at onset 2.5 - 10 10 - 21 > 21 > 18 > 18 > 2 highly variable,
mostly > 40
Myelopathy - Possible at a
preclinical
stage
+ or - + + - +
White matter
lesions on
brain MRI
Extensive Extensive Extensive Wallerian degeneration
of the
parieto-occipital, frontal,
or
- Very rare
corticospinal tracts
in brain-stem,
pons and internal
capsules
involving the centrum
semiovale
Wallerian degeneration
of the corticospinal
tracts in brain-stem, pons
and internal capsules is
less common than in
males with AMN
Behavioral
and cognitive
disorder
+ + + - + - Very rare
Peripheral
neuropathy
- rare possible Sensory-motor,
mostly axonal,
rarely
demyelinating
Sensory-motor,
mostly axonal
- +/−
Endocrine
disorder
often AD often AD often AD often AD and
testicular
insufficiency
often AD and
testicular insufficiency
AD AD rare (< 1%)
Progression rapid rapid rapid slow rapid - slow
- = absent; + = present; CCALD = childhood cerebral ALD; AdolCALD = adolescent cerebral ALD; ACALD = adult cerebral ALD; AMN = adrenomyeloneuropathy; AD
= Addison-disease.
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Phenotypes in male X-ALD patients
Addison-only
Adrenocortical insufficiency (or even an Addisonian cri-
sis) can be the presenting symptom of X-ALD in boys
and men, years or even decades before the onset of
neurological symptoms. X-ALD is a frequent cause of
Addison’s disease in boys and adult males [27,28], in
particular when circulating adrenocortical autoanti-
bodies are absent [29]. A percentage as high as 35 has
been reported [27]. However, this figure may be overesti-
mated. Indeed, in a study of 40 Dutch men with adreno-
cortical insufficiency, no patients with X-ALD were
identified (B.M. van Geel BM and J. Assies unpublished
data). Recognizing that Addison’s disease is due to X-
ALD has important implications for genetic counseling
but also management. It is therefore important to con-
sider X-ALD in any boy or adult male presenting with
Addison’s disease. Adrenocortical insufficiency initially
affects the glucocorticoid function of the adrenal, but
the mineralocorticoid function is ultimately deficient in
approximately half of the X-ALD patients [27].
Cerebral ALD (childhood, adolescent and adult)
These phenotypes are the most rapidly progressive and
devastating phenotypes of X-ALD. They most frequently
present in childhood (childhood cerebral ALD; CCALD),
however never before the age of 2.5 years [30,31]. The
onset of CCALD is insidious, with deficits in cognitive
abilities that involve visuospatial and visuomotor func-
tions or attention and reasoning. In boys and adolescents
it initially results in a decline of school performance.
These early clinical symptoms are often misdiagnosed as
attention deficit hyperactivity disorder and can delay the
diagnosis of CCALD. As the disease progresses, more
overt neurologic deficits become apparent, which include
withdrawn or hyperactive behavior, apraxia, astereogno-
sia, auditory impairment ("word deafness'' reflecting im-
pairment in acoustic analysis of word sounds), decreased
visual acuity, hemiparesis or spastic tetraparesis, cerebel-
lar ataxia and seizures. At this stage progression is ex-
tremely rapid and devastating. Affected boys can lose the
ability to understand language and walk within a few
weeks. Eventually, patients are bedridden, blind, unable
to speak or respond, requiring full-time nursing care and
feeding by nasogastric tube or gastrostomy. Usually death
occurs two to four years after onset of symptoms, or - if
well-cared for - patients may remain in this apparent
vegetative state for several years [30].
The rapid neurologic decline of CCALD is caused by a
severe inflammatory demyelination process primarily
affecting the cerebral hemispheres. Postmortem histo-
pathological examination of brain tissue reveals exten-
sive demyelination with perivascular infiltration of
lymphocytes and macrophages that resembles, to some
extent, the demyelinating lesions seen in multiple scler-
osis [32]. In 80% of patients the initial demyelinating le-
sion is localized in the splenium of the corpus callosum
and progresses to involve the adjacent parieto-occipital
white matter [33]. Alternatively, the initial demyelinating
lesions may occur in the genu of corpus callosum and
then progress symmetrically or asymmetrically to the
white matter of the frontal lobes [33]. The lesions may
also initially involve the pyramidal tracts within the pons
or the internal capsules and then extend into the white
matter of the centrum semiovale. Brain MRI shows ab-
normal signal intensities (increased signal on T2 and
FLAIR sequences, decreased signal on the T1 sequence)
in the corpus callosum, parieto-occipital or frontal white
matter or pyramidal tracts within the brainstem, pons
and internal capsules (Figure 1). Atypical patterns of de-
myelination, for instance highly asymmetrical disease
have been described [34]. Initially, the demyelinating
lesions do not show enhancement on T1 sequences after
intravenous gadolinium administration. The presence of
gadolinium enhancement of demyelinating lesions
occurs usually in a second stage when the disease starts
to progress rapidly, reflecting severe inflammation and
disruption of the blood brain barrier. This transition to
the rapidly progressive neuroinflammatory stage may
occur very early, even when the demyelinating lesions
are restricted to the corpus callosum or pyramidal tracts
or later, once the demyelinating lesions have already sig-
nificantly extended into the cerebral white matter. In the
absence of biomarkers to predict this evolution, brain
MRI remains the only tool to detect this evolution in an
early stage. A scoring system to grade the demyelinating
abnormalities on brain MRI has been developed by Loes
[35]. This score correlates well with neurologic symp-
toms when the demyelinating lesions involve the
parieto-occipital white matter. However, lesions in the
frontal white matter can produce severe symptoms (es-
pecially behavioral), while the Loes score is still low. Less
frequently, cerebral demyelination as the presenting
phenotype of X-ALD occurs in adolescence (AdolCALD)
or adulthood (ACALD). The symptomatology in these
patients strongly resembles CCALD, but the initial pro-
gression of symptoms usually is slower. In adults, the
early cognitive decline is rarely recognized by their fam-
ilies and friends or at work. As the disease progresses,
psychiatric disturbances mimicking schizophrenia or
psychosis are not uncommon [36]. In those cases, the
diagnosis of X-ALD is often delayed; particularly when
no family history of X-ALD is present and when clinical
symptoms of Addison's disease are absent.
Approximately 10% of boys or adolescents with cerebral
ALD may not develop the rapidly progressive neuroin-
flammatory stage of the disease. The same may occur in
men with ACALD or in men with AMN who develop
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secondary cerebral demyelination (see below). This cere-
bral demyelinating form of X-ALD is often referred to as
“chronic or arrested cerebral X-ALD”. The cerebral de-
myelinating process arrests spontaneously and the patient
can remain stable for a decade or even longer. But even
after a 10–15 year period of stability, sudden onset of
rapid neurologic deterioration may occur, reflecting a full
progression to the neuroinflammatory stage of the disease.
Adrenomyeloneuropathy (AMN)
Virtually all patients with X-ALD who reach adulthood
develop AMN, usually in the 3rd and 4th decade. Initial
symptoms are limited to the spinal cord and peripheral
nerves. Patients develop gradually progressive spastic
paraparesis, sensory ataxia with impaired vibration sense,
sphincter dysfunction (mostly urinary), pain in the legs
and impotence [37]. The clinical burden of peripheral
nerve involvement is usually moderate and difficult to
assess because of prominent spinal cord symptoms. If
polyneuropathy is investigated electrophysiologically, an
axonopathy is found in the majority of the patients [38].
Rarely, the initial symptomatology may be that of a per-
ipheral neuropathy, either demyelinating or axonal
[39,40].
Before the availability of MR imaging, AMN was often
misdiagnosed as multiple sclerosis or hereditary spastic
Figure 1 MRI of the brain in a case of childhood cerebral ALD showing characteristic extensive white matter changes in the parieto-
occipital region and internal capsules on FLAIR sequences (A). This area is initially affected in about 80% of cases of cerebral ALD. The rim
enhances after administration of gadolinium on T1 sequences (B). In about 20% of cases the site of initial involvement in cerebral ALD is the
frontal white matter as shown on this FLAIR image of a different patient with cerebral ALD (C), with prominent rim enhancement after
administration of gadolinium on a T1 weighted image (D).
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paraparesis (HSP). The pathological basis of AMN is a
noninflammatory distal axonopathy that involves the
long tracts of the spinal cord and, to a lesser extent, the
peripheral nerves [41]. This phenotype is in most cases
slowly progressive, causing severe motor disability of the
lower limbs over one or two decades but mild or no sig-
nificant deficits in arms and hands. Brain MRI is normal
or may show subtle abnormalities such as moderately
increased signal intensities of the pyramidal tracts in
brainstem, pons and internal capsules on FLAIR and T2
sequences that reflect likely Wallerian degeneration in
patients with longstanding symptoms of AMN (Figure 2).
These abnormalities are not considered manifestations
of cerebral ALD. However, if the increased signal of the
pyramidal tracts becomes more intense and extends be-
yond the internal capsules into the white matter of the
centrum semiovale, this is considered a manifestations
of cerebral ALD (Figure 3). MRI of the spinal cord even-
tually shows non-specific atrophy, but no demyelination
or gadolinium enhancement as seen in multiple scler-
osis. In contrast, magnetization transfer or diffusion
tensor-based imaging sequences show significant abnor-
malities of the spinal cord tracts [42-44].
A retrospective study revealed that over a period of
10 years, approximately 20% of AMN patients developed
additional cerebral demyelination [45]. After an initial
progression demyelinating lesions can stabilize spontan-
eously leading to moderate cognitive deficits. However,
once the cerebral demyelinating lesions have entered the
active phase of neuroinflammation with gadolinium en-
hancement, the prognosis is as poor as in CCALD. The
neurologic symptoms of AMN patients that develop
cerebral ALD are identical to those observed in adults
with adult cerebral ALD, with additional symptoms of
the pre-existing myelopathy. Approximately 70% of
AMN patients have adrenocortical insufficiency [46]. An
equal percentage of affected males have subclinical signs
of testicular insufficiency [47]. Clinical symptoms of tes-
ticular insufficiency are rare. Hair of patients with AMN
is often thin and sparse; these patients often show bald-
ing at an early age (Figure 4). This typical scanty scalp
hair was first described in 1955 [23].
Women with X-ALD
As in many X-linked diseases, it was assumed that fe-
male carriers remain asymptomatic. However, many
women develop AMN-like symptoms [48]. Physical
examination of a large group of female carriers attending
family conferences in the United States revealed that
more than 50% had some kind of abnormality on neuro-
logic examination [30]. An increasing number of symp-
tomatic heterozygous women are identified as the first
member of their family to be affected by X-ALD and the
real incidence of AMN in heterozygous women is likely
to be close to 65% by the age of 60 years (Engelen et al,
manuscript in preparation). Onset of neurologic symp-
toms mainly occurs between the 4th and 5th decade and
they are very similar to those observed in adult males
with AMN. Sensory ataxia, fecal incontinence and pain
in the legs are however often more prominent in symp-
tomatic women with AMN. Cerebral involvement and
adrenocortical insufficiency are rare, 2% and 1%, respect-
ively [30,49]. So far, neither have been documented in
the Netherlands and France. It is speculated that skewed
Figure 2 MRI of the brain in a patient with AMN showing increased signal in the pyramidal tracts on T2-weighed coronal (A) and axial
(B) images indicative of Wallerian degeneration.
Engelen et al. Orphanet Journal of Rare Diseases 2012, 7:51 Page 5 of 14
http://www.ojrd.com/content/7/1/51
X-inactivation in neuronal cells may contribute to the
manifestation of neurologic symptoms in X-ALD carriers
[50,51]. In a recent study the association of skewed X-
inactivation and symptomatic status could not be con-
firmed [52]. However, this may be attributable to differ-
ences in mean age between the symptomatic and
asymptomatic group in this study.
Asymptomatic and pre-symptomatic patients
A diagnosis of X-ALD must be followed by extended
family screening together with a geneticist. This enables
the detection of: 1) heterozygous women who can be
offered prenatal or in some countries preimplantation
diagnosis for future pregnancies, and 2) boys or adult
males who are asymptomatic but at risk to develop cere-
bral demyelination or adrenocortical insufficiency [8]. It
is important to detect these complications as early as
possible for treatment, as described in the section on
‘clinical management’.
Evolution over time
X-ALD phenotypes are not static. Presymptomatic males
are nearly all at risk to develop neurologic (cerebral
ALD, AMN) or endocrinologic (Adisson’s disease) symp-
toms. Addison-only males can develop AMN or cerebral
ALD and AMN males can develop cerebral demyelin-
ation. It is estimated that over a period of 10 years about
20% of patients with AMN will progress to a cerebral
Figure 3 MRI of the brain (T2 (A) and FLAIR (C) images; T1 with gadolinium (B, D)) of a patient with AMN who rapidly deteriorated
clinically with new symptoms of cognitive decline. On MRI extensive white matter changes were seen in the parieto-occipital white matter
and corpus callosum (A), but no enhancement of the lesion after administration of gadolinium (B). A follow-up MRI about 3 months later shows
progression of the white matter lesion (C) and there is now faint enhancement of the rim of the lesion after gadolinium administration (D).
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phenotype [45]. Presymptomatic women with X-ALD
are mostly at risk to develop AMN. Progression of X-
ALD in a specific individual can not be predicted.
X-ALD is characterized by the absence of a genotype-
phenotype correlation. In spite of identical ABCD1 gene
mutations, patients can have markedly divergent neuro-
logical and neuropathologic characteristics [53,54].
There is ample evidence that other genetic and/or envir-
onmental factors may influence the clinical presentation
of X-ALD. Segregation analysis suggests that the pheno-
typic variability is due to at least one autosomal modifier
gene [55,56]. Head trauma may be an environmental fac-
tor triggering the onset of cerebral ALD [57]. Other
brain lesions, like a stroke, may also trigger cerebral de-
myelination in patients with X-ALD.
Etiology and pathophysiology
X-ALD is caused by mutations in the ABCD1 gene
located on the X-chromosome. So far, 600 different
mutations have been identified (see http://www.x-ald.nl).
ABCD1 encodes ALDP, a peroxisomal transmembrane
protein involved in the transport of VLCFA-CoA esters
from the cytosol into the peroxisome [5,6,58]. ALDP de-
ficiency leads to impaired VLCFA beta-oxidation (about
30% of normal) and the accumulation of VLCFA-CoA
esters in cells. The VLCFacyl-CoA esters in the cytosol
are incorporated into various lipid fractions and are also
substrate for further elongation to even longer fatty acids
[6,59]. ELOVL1 (elongation of very-long-chain-fatty
acids) is the single elongase catalyzing the synthesis of
both saturated VLCFA (C26:0) and mono-unsaturated
VLCFA (C26:1). ELOVL1 expression is not increased in
X-ALD fibroblasts, but increased synthesis of VLCFA is
due to increased substrate availability [6].
Various in vitro experiments have demonstrated that
VLCFA accumulation is toxic. VLCFA are extremely
hydrophobic and their rate of desorption from biological
membranes is about 10,000 times slower than that of
long-chain fatty acids causing disruptive effects on the
structure, stability and function of cell membranes
[60,61]. Excess of VLCFA in cultured cells decreases the
ACTH-stimulated cortisol release by human adrenocor-
tical cells [62] and causes cell death in astrocytes and
oligodendrocytes [63]. In vivo, VLCFA cause oxidative
stress and oxidative damage to proteins [64,65] micro-
glial activation and apoptosis [66]. VLCFA-induced oxi-
dative stress may contribute to axonal damage in the
spinal cord of Abcd1 knock-out mice that develop an
AMN-like phenotype [64,67]. In addition, a dysregula-
tion of oxidative phosphorylation, adipocytokine and in-
sulin signaling pathways, and protein synthesis was
recently shown in the spinal cord of Abcd1 knock-out
mice [68].
The neuropathological hallmark of AMN is an axono-
pathy with microgliosis but without significant myelin
changes. It is therefore likely that the primary conse-
quence of VLCFA accumulation impairs the capacity of
oligodendrocytes and Schwann cells to sustain axonal in-
tegrity, resulting in axonal damage.
The VLCFA homeostasis in X-ALD is disturbed [59].
This may contribute to the destabilization of the myelin
sheath and impair the function of astrocytes and micro-
glia which play an important role in myelin integrity
[63,66]. Not all males with X-ALD develop cerebral ALD
Figure 4 Thin and scanty scalp hair in a man with X-ALD (AMN phenotype). Written informed consent was obtained from the patient for
publication of these images.
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corroborating the notion that additional triggers, genetic,
epigenetic and/or environmental, modify this process.
In the absence of a relevant X-ALD mouse model
that develops cerebral demyelination with neuroinflam-
mation, the pathogenic processes that result in cerebral
demyelination and subsequently severe neuroinflamma-
tion remains therefore poorly understood.
Biochemical and molecular diagnosis
Newborn screening is now technically feasible [9]. It is
based on the measurement of C26:0 lysophosphatidyl-
choline (26:0-lyso-PC) in dried blood spots. It will
lead to identification of pre-symptomatic patients with
X-ALD. Whether this screening is implemented is a
matter of national policy and dependent on ethical
considerations.
If X-ALD is suspected in a male with neurological
symptoms (with or without typical brain MRI abnormal-
ities) or Addison’s disease, demonstration that VLCFA
are elevated in plasma confirms the diagnosis. For
women with X-ALD, the diagnostic test of choice
is mutation analysis of the ABCD1 gene, because
15% of women with X-ALD have normal plasma
VLCFA levels [37]. Family screening follows the same
recommendations.
The ABCD1 gene is the single causative gene for X-
ALD [4]. It is an X-linked inherited disorder. Therefore
all daughters of an affected male are obligate carriers
whereas his sons can never be affected. When a woman
carries the gene for X-ALD, there is a 50% probability
for each pregnancy that the gene is transmitted to a son
or daughter. The frequency of de novo mutations in the
index case is estimated to be around 4% [69] which indi-
cates that the ABCD1 mutation occurred in the germ
line. There is evidence of gonadal or gonosomal mosai-
cism in less than 1% of patients which means an
increased risk of an additional affected offspring.
Differential diagnosis
Symptoms
In boys and men presenting with Addison’s disease,
including those who have only a glucocorticoid
deficiency, and in whom there are no detectable
steroid-21-hydroxylase or other organ-specific anti-
bodies, X-ALD should be considered and determination
of plasma VLCFA levels must be performed [70,71].
Young boys and adult males presenting with cognitive
and neurological symptoms with (usually enhancing)
white matter lesions on brain MRI should be tested for
X-ALD.
In adult men, the most common presenting symptom
of X-ALD is a chronic myelopathy. In the past, AMN
was often misdiagnosed as primary progressive multiple
sclerosis or hereditary spastic paraparesis. After ruling
out a compressive myelopathy by MRI of the spinal cord
and other common causes of chronic myelopathy (some
possible diagnoses for chronic myelopathy with a (near)
normal MRI are summarized) [72], X-ALD should be
considered. A clinical clue to the diagnosis can be the
presence of adrenocortical insufficiency and early bald-
ness. However, even in the absence of clinical signs of
adrenocortical insufficiency AMN should be considered.
Differential diagnosis of chronic myelopathy with nor-
mal MRI:
Deficiencies: Vitamin B12, folic acid, copper
Hereditary spastic paraparesis with amyotrophy
Infections (e.g., HTLV-1, HIV)
Primary lateral sclerosis
Radiation myelopathy
Cerebrotendinous xanthomatosis
Metachromatic leukodystrophy
Krabbe disease
A category that remains underdiagnosed relatively
often are women with AMN. Physicians familiar with X-
ALD are aware that it is not uncommon that women
with X-ALD develop a myelopathy [46]. However, most
neurology textbooks do not list X-ALD in the differential
diagnosis for chronic myelopathy in women. The diag-
nosis can only be excluded by ABCD1 mutation analysis.
As mentioned before, there is an increasing number of
X-ALD families in which the index case is a woman with
clinical symptoms of AMN.
Increased VLCFA
Increased plasma VLCFA are not pathognomonic for X-
ALD or might even be false positive, because of
hemolysis of the sample or dietary causes, for example a
ketogenic diet [73]. Alternatively, some dietary products
like rapeseed oil or mustard seed oil that are rich in eru-
cic acid (C22:1) can result in the lowering of C26:0
therefore causing a false negative result (Ann Moser,
personal communication). If metabolic screening reveals
increased VLCFA, the next step is to confirm the diag-
nosis by performing ABCD1 mutation analysis. If this is
negative, it is important to consider other peroxisomal
disorders, such as 1) peroxisomal biogenesis disorders
with late onset of symptoms [74,75] (Ebberink et al, in
press), and 2) peroxisomal acyl-CoA oxidase 1 (ACOX1)
or D-bifunctional enzyme (DBP) deficiency with late
onset of symptoms. This requires further testing for bile
acid intermediates, phytanic and pristanic acids in
plasma, and plasmalogens in erythrocytes [76]. A further
metabolic screening of peroxisomal dysfunction must
also be performed on skin fibroblasts, at least by per-
forming catalase immunofluorescence after culturing
cells at 37°C, but also at 40°C [77].
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White matter changes on MRI
In males with confluent white matter changes, X-ALD
should be considered, especially when there is increased
signal intensity on T2-weighed and FLAIR sequences in
the parieto-occipital region and the splenium of the cor-
pus callosum [33]. Rim enhancement of demyelinating
lesions is usually observed when boys or adult males
present with overt neurological symptoms from cerebral
ALD. Therefore, intravenous administration of gadolin-
ium is advised if X-ALD is considered. However, in
about 20% of males with X-ALD, the white matter
changes occur predominantly in the genu of corpus cal-
losum and frontal lobes, or involve the pyramidal tracts
with extension in the white matter of the centrum semi-
ovale [33]. The brain MRI pattern of cerebral X-ALD is
usually readily recognized by neuroradiologists. A help-
ful algorithm for diagnostic work-up of patients with
white matter changes on brain MRI is suggested by
Schiffmann and Van der Knaap [78].
There are other peroxisomal disorders that present
with MRI abnormalities resembling X-ALD, in particular
peroxisomal biogenesis disorders and ACOX1 or DBP
deficiency with late onset of symptom [79]. Although
the radiologic findings might suggest X-ALD, the clinical
presentation is very different and therefore these disor-
ders are easily differentiated.
Genetic counseling and prenatal diagnosis
Genetic counseling must be offered to the parents
of affected boys, adult males and women with X-ALD
and their family to detect: 1) carriers who can be
offered prenatal diagnosis, and 2) asymptomatic or pre-
symptomatic men or women who can benefit from
therapeutic interventions. Regular follow-up in presymp-
tomatic males can prevent serious morbidity and
mortality.
ABCD1 mutational analysis can be performed either
on a fresh chorionic villus sample at 11–13 weeks of
pregnancy or on amniotic cells obtained from amniotic
fluid after centrifugation at 15–18 weeks of gestation
[80]. In some countries, pre-implantation genetic diag-
nosis is available. If the fetus is a female, there is no con-
sensus with respect to prenatal diagnosis and
termination of pregnancy, due to the highly variable ex-
pression of disease in women with X-ALD. Cases will be
evaluated on an individual basis.
Clinical management
The flowchart in Figure 5 summarizes the recommenda-
tions for follow-up of boys and men with X-ALD.
Boys and adult males with X-ALD
Follow-up in boys and men with X-ALD is important for
two reasons: 1) early detection of adrenocortical insuffi-
ciency and 2) early detection of cerebral ALD to propose
allogeneic hematopoietic stem cell transplantation
(HCT) if a HLA-matched donor or cord blood is avail-
able. Despite significant mortality risk, allogeneic HCT
remains the only therapeutic intervention that can arrest
the progression of cerebral demyelination in X-ALD,
Figure 5 Flowchart describing the outpatient management of X-ALD. *If there is no gadolinium enhancement present, consider arrested
cerebral ALD and repeat the MRI in 3 months.
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provided the procedure is performed very early, i.e.,
when affected boys or men have no or minor symptoms
due to cerebral demyelinating disease [81,82].
In the future, transplantation of autologous
hematopoietic stem cells that have been genetically cor-
rected with a lentiviral vector before re-infusion might
become an alternative to autologous HCT, once the very
encouraging results obtained in the first two treated
patients will have been extended to a larger number of
patients with cerebral X-ALD [83].
If boys or men do not have Addison’s disease it is
recommended that they are evaluated yearly by an endo-
crinologist for adrenocortical dysfunction by measuring
the plasma ACTH levels and performing an ACTH
stimulation test [71]. Steroid replacement therapy can
then be initiated if necessary.
Boys without neurological deficits should be moni-
tored closely for radiological signs of cerebral ALD.
CCALD has not been reported before the age of 2.5 years
[8]. We recommend an MRI of the brain every 6 months
in boys aged 3 to 12 years old to screen for early signs of
CCALD. If symptoms occur suggestive of cerebral ALD
(for instance declining school performance) the MRI
should be performed at the earliest available opportun-
ity, but it is our experience that the detection of brain
MRI abnormalities precedes any detectable cognitive
dysfunction by at least 6 months to 1 year. After the age
of 12 years, the incidence of CCALD decreases, but an
MRI scan must be performed yearly or earlier if new
symptoms occur. It is important to detect cerebral ALD
as early as possible, preferably in the asymptomatic stage
with only moderate radiological abnormalities to discuss
the possibility to perform allogeneic HCT. Accordingly,
if a brain MRI shows abnormalities, even very limited
such as an increased signal intensity on T2 or FLAIR
sequences in the splenium or genu of the corpus callo-
sum, brain MRI must be repeated within 3 months to
evaluate disease progression and in particular to identify
the presence of gadolinium rim enhancement of lesions.
Because the disease can be very rapidly progressive, it is
strongly advised to discuss the possibility of allogeneic
HCT as soon as brain MRI abnormalities typical of cere-
bral ALD are detected. After a successful transplant, the
lesions on MRI stabilize and even regress. Treatment
results are better the earlier treatment is started [82].
For adult men with or without signs of AMN, we ad-
vise evaluation by a neurologist yearly or bi-annually to
screen for symptoms of AMN and to administer symp-
tomatic treatment if necessary (for instance, medication
against spasticity). Referral to a rehabilitation physician
and urologist will often become necessary.
Adult men can develop cerebral ALD and in our cen-
ters, we offer an MRI of the brain every single year
[30,45]. There is no proven treatment for cerebral ALD
in adults. It seems likely that allogeneic HCT is also ef-
fective in adults with early stage cerebral ALD, but there
are no published studies or cases describing this treat-
ment. We tend to consider allogeneic HCT in an adult
patient with early stage cerebral ALD, after carefully
counseling the patient about the lack of evidence for the
treatment and the risk of the procedure which is signifi-
cantly higher than in boys. Whereas the onset of demye-
linating lesions involving the corpus callosum and
adjacent parieto-occipital or frontal white matter leaves
no doubt about the onset of cerebral ALD, the situation
is different when there are only slightly increased signal
abnormalities in the pyramidal tracts of AMN patients
that gradually become more intense and involve the
white matter of the centrum semiovale. This can herald
the onset of cerebral ALD, but can also reflect Wallerian
degeneration in severe AMN.
For AMN there is no effective disease modifying ther-
apy available yet. Although Lorenzo’s oil (LO) had great
promise, several open-label trials have shown that the
disease progresses even when plasma VLCFA are nor-
malized by LO treatment [84,85]. A large randomized
placebo-controlled clinical trial was designed to provide
a definitive answer, but was unfortunately aborted before
completion by the safety monitoring board because of
presumed side effects of the placebo treatment. There is
also a retrospective study suggesting that if presympto-
matic boys are started on LO, it may delay the onset of
neurological symptoms [86]. We consider the scientific
evidence to support the efficacy of LO weak, and do not
offer this treatment to our patients. Regular follow-up in
AMN remains important, however, mainly to provide
symptomatic treatment.
Lovastatin also lowered plasma VLCFA [87], but a
placebo-controlled trial revealed that lovastatin did not
have an effect on the C26:0 levels in peripheral blood
lymphocytes and erythrocytes nor on the VLCFA con-
tent of the low-density lipoprotein fraction [88].
More research and new treatments strategies are des-
perately needed, especially for those affected by AMN,
which is relentlessly progressive and causes severe dis-
ability. Antioxidants reduce markers for oxidative stress
and axonal degeneration in the spinal cord of Abcd1
knockout mice [89]. Based on this observation a clinical
trial with anti-oxidants in X-ALD is ongoing in Spain.
Women with X-ALD
Women with X-ALD should be evaluated for the devel-
opment of neurologic symptoms. Since women with X-
ALD very rarely develop adrenocortical insufficiency or
cerebral involvement, periodic evaluation of adrenocorti-
cal function and brain MRI is not mandatory [37].
Greater awareness among physicians that women can
develop neurologic symptoms is important for
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counseling but also to prevent unnecessary diagnostic
tests and erroneous diagnosis. We know of cases of
women with X-ALD who underwent cervical laminec-
tomy for presumed cervical spondylogenic myelopathy.
For symptomatic women with X-ALD, we advise (as for
men with AMN) a yearly evaluation by a neurologist to
discuss the indication of rehabilitation, the referral to an
urologist and treatment of spasticity and neuropathic
pain.
Prognosis
It is debatable whether men with X-ALD can remain
really asymptomatic for life. It seems probable that there
is only presymptomatic X-ALD in men. Although there
is no large prospective cohort study to accurately deter-
mine the natural history of the disease, several general
observations can be made. It is likely that all patients
with X-ALD if they survive into adulthood eventually
develop myelopathy, i.e. AMN. Usually, symptoms and
signs occur from the 3rd decade of life, but much earlier,
or much later, is possible. The severity and progression
cannot be predicted for individual patients. There is
marked variability ranging from men with X-ALD that
are wheelchair bound by the age of 25 and others who
are able to walk with a cane while in their seventies. This
is important when counseling patients: symptoms will
occur, but only time will tell how severely affected an in-
dividual will be.
Not every boy or man with X-ALD will develop cere-
bral ALD. About 35-40% of boys with an ABCD1 muta-
tion will develop CCALD before reaching adulthood. It
can still not be predicted who will develop this devastat-
ing manifestation of the disease. Previously it was
believed that after reaching adulthood this complication
was very rare. However, it is now well established that at
least 20% of adult males with the AMN phenotype will
develop cerebral demyelination later in life [45]. If this
occurs, these patients have the same poor prognosis as
boys with inflammatory cerebral ALD.
It is well documented that women develop symptoms
that resemble AMN [46], but there is no prospective
study with adequate numbers to really estimate what
percentage of women become symptomatic. We recently
completed a large prospective cohort study to describe
the symptomatology of X-ALD in women (Engelen et al,
manuscript in preparation).
Unresolved questions and future research
For the majority of patients with X-ALD there is cur-
rently no curative or preventive treatment. However,
several promising new approaches will hopefully come
to fruition in the future. For example, it has been
demonstrated in X-ALD cells that small interfering RNA
(siRNA)-mediated inhibition of ELOVL1 reduces VLCFA
synthesis and levels [6]. Compounds that can inhibit
ELOVL1 are therefore interesting candidates for new
preventive treatments. We demonstrated that bezafibrate
which is both an effective, safe and well-tolerated com-
pound lowers the levels of VLCFA in X-ALD cells by
inhibiting VLCFA synthesis (Engelen et al., in press
http://dx.doi.org/10.1007/s10545-012-9471-4). A clinical
trial to evaluate its in vivo efficacy in X-ALD patients is
ongoing.
As mentioned before, it is likely that several modifier
genes play a role in the onset and severity of AMN, the
onset of cerebral ALD and the progression to the rapidly
progressive neuroinflammatory stage. However, so far no
major modifier genes have been identified that could
lead to the development of a genetic test to predict
phenotype and disease evolution. The eventual pheno-
type of X-ALD in an individual will most likely be deter-
mined by the combination of several epigenetic and
environmental modifiers, most of which have not been
identified. Much research is currently focused on identi-
fying these modifiers to better predict clinical outcome
in individual patients.
An important issue is the systematic characterization
of disease manifestations in women with X-ALD. Clin-
ical research has always focused on boys and men and
women were often considered “carriers” with no or min-
imal symptoms. For adequate counseling this informa-
tion is important and should be available.
For clinicians caring for patients with AMN it is well
known that cerebral demyelination can occur. It is im-
portant to systematically study if an allogeneic HCT can
be successful in these cases and even arrest the progres-
sion of myelopathy.
Conclusions
Pediatricians, endocrinologists, neurologists and psychia-
trists may encounter X-ALD which is a relatively com-
mon metabolic disorder in their practice. The disorder is
associated with severe morbidity and mortality in the
majority of affected patients. Recognition of X-ALD is
highly important, since in some cases treatment is avail-
able, such as allogeneic HCT in the early stage of
CCALD and endocrine replacement therapy for adreno-
cortical insufficiency. Furthermore, prenatal testing to
prevent unnecessary new cases of this devastating dis-
ease is available.
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